GOSS Stock Forecast & Price Target

Gossamer Bio Inc. has shown significant positive movement in its clinical trial for Seralutinib, with a statistically significant placebo-adjusted improvement of approximately 20-25 meters in six-minute walk distance (6MWD) at the 48-week mark, indicating meaningful clinical benefits for patients. The trial reported an impressive +28.2 meters improvement from the baseline for the Seralutinib group compared to +13.5 meters for the placebo, and subgroup analyses highlighted additional improvements exceeding 30 meters in functional class III patients, reflecting Gossamer’s commitment to addressing critical needs in pulmonary arterial hypertension (PAH). Furthermore, unlike many existing PAH treatments that exhibit plateauing benefits, Seralutinib has demonstrated a continued improvement across key measures over a sustained period, bolstering the company’s long-term growth potential in this therapeutic area.

Gossamer Bio's financial outlook has been significantly downgraded, with FY32 total revenue estimates revised from $993 million to $324 million due to disappointing PROSERA trial data and muted results in 6MWD. The company's projected value has further decreased, with an increased discount rate leading to a target estimate of approximately $1 per share, raising concerns about its long-term viability. Additionally, uncertainties surrounding the registrational path for seralutinib, compounded by potential limitations in gaining market traction, contribute to a negative sentiment regarding the company’s future performance.